Deferiprone for transfusional iron overload in sickle cell disease and other anemias: open-label study of up to 3 years
Sign Up to like & getrecommendations! Published in 2022 at "Blood Advances"
DOI: 10.1182/bloodadvances.2021006778
Abstract: Key Points • Long-term deferiprone therapy was not associated with new safety concerns in patients with SCD or other anemias.• Long-term deferiprone therapy led to continued and progressive reduction in iron load in patients with… read more here.
Keywords: iron overload; transfusional iron; overload sickle; iron ... See more keywords